Abstract
The inhibitory activity of whole urines from 32 healthy subjects and 50 calcium oxalate renal stone formers was assessed in terms of (a) their ability to withstand increasing quantities of oxalate before undergoing spontaneous nucleation of calcium oxalate, and (b) their response to a standard 30-μmol challenge of oxalate above their measured metastable limits. The concentrations of calcium ( p <0.05), oxalate ( p <0.05), urate ( p <0.01) and glycosaminoglycans ( p < 0.005) were significantly lower in the stone formers than in the controls and were associated with a significantly higher 24-h urinary volume ( p < 0.001). The majority of urine samples precipitated envelope crystals of calcium oxalate dihydrate, while the remainder precipitated the monohydrate. A significantly ( p < 0.02) greater proportion of the urines from stone formers than from controls deposited calcium oxalate monohydrate, and this was attributed to a lower concentration of calcium in these urines. The minimum amounts of oxalate necessary to induce crystal nucleation did not differ between the two groups, but when the measured metastable limits were expressed as the product of the total (i.e. endogenous + that added to induce nucleation) concentrations of oxalate and calcium at which precipitation occurred, then these limits were significantly lower ( p < 0.05) in the stone formers than in the healthy subjects. However, when the metastable limits of a subgroup of stone formers and controls matched for 24-h urinary volume and calcium and urate concentrations were compared, no differences between the groups could be discerned. The urines from the two groups of subjects were indistinguishable with respect to their responses to the oxalate load, whether these were expressed as rate of crystal growth, total amount of calcium oxalate deposited during a given time or size of the precipitated crystals. It was concluded that the lower metastable limits of the stone formers were a consequence of reduced concentration, rather than output, of urinary inhibitors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.